



HORIZON EUROPE

THE EU RESEARCH & INNOVATION PROGRAMME

2021 – 2027

George Bonas,
Global Service Facility of the EC



NCP TRAINING – PRESENTATION & GROUP WORK

Selecting and advertising HEU Calls for clients



Step 1: Find the right HEU Calls

- 1. Published Work Programmes:** <https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/reference-documents>
 - + Several thematically sorted documents, covering one specific area of HEU (e.g. Health, Widening...)
 - + Information is available well in advance (eventually you can get even access to Draft WP's)
 - No filter options available
- 2. Search Mask:** <https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-search>
 - + Diverse filtering options
 - + always up to date
 - calls only visible when published
 - no central document
- 3. Dedicated events/webinars:** depending on host organisation
 - + Calls are presented and explained
 - + Possibility to ask questions
 - only at a certain time

Funding and Tenders Portal (Search Mask)



Funding & tender opportunities
Single Electronic Data Interchange Area (SEDIA)

English EM

Register Login

SEARCH FUNDING & TENDERS HOW TO PARTICIPATE PROJECTS & RESULTS WORK AS AN EXPERT SUPPORT Get started

Horizon Europe (HORIZON) clear filter

Grant and Audit Management Services may not be accessible due to the issues experienced by the European Commission Authentication Service (EU Login).
The Expert Registration, Legal Entity, Bank Account, Contracts and Payment functionalities in the Experts Area of the F&T Portal **may be unavailable** due to the issues experienced by the European Commission Authentication Service (EU Login).

Type your Keywords...

Match whole words only

GRANTS TENDERS

Submission status

Forthcoming (132) Open for submission (77) Closed (340)

Programming period

Select a Programme period...

Horizon Europe (HORIZON)

Programme part

Climate, Energy and Mobility

Mission

Select a Mission...

Funding and tenders (549) Need help? Calendar Feed Sort by: Submission status

Support to the activities of technology areas of the SET Plan: Action dedicated to energy efficiency in industry Call for proposal Grant
HORIZON-CL5-2022-D4-02-06

Programme	Horizon Europe (HORIZON)	Status	Open for submission
Type of action	HORIZON Coordination and Support Actions	Deadline model	single-stage
Opening date	06 September 2022	Deadline date	24 January 2023 17:00:00 Brussels time

Thermal management and energy optimisation of high energy demand IT systems equipment in tertiary buildings Call for proposal Grant
HORIZON-CL5-2023-D4-01-04

Programme	Horizon Europe (HORIZON)	Status	Open for submission
Type of action	HORIZON Research and Innovation Actions	Deadline model	single-stage
Opening date	13 December 2022	Deadline date	20 April 2023 17:00:00 Brussels time

Integrated real-time digital solutions to optimise navigation and port calls to reduce emissions from shipping (ZEWTP Partnership) Call for proposal Grant
HORIZON-CL5-2023-D5-01-13

Programme	Horizon Europe (HORIZON)	Status	Open for submission
Type of action	HORIZON Innovation Actions	Deadline model	single-stage



Call example

Future-proofing historical buildings for the clean energy transition

HORIZON-CL5-2023-D4-01-02

Programme Horizon Europe (HORIZON)

Type of action HORIZON Research and Innovation Actions

Opening date 13 December 2022

Status

Deadline model

Deadline date

Call for proposal

Grant

Open for submission

single-stage

20 April 2023 17:00:00
Brussels time

Deconstructing a call text

Topic ID

HORIZON-CL6-2021-BIODIV-01-11: What else is out there? Exploring the connection between biodiversity, ecosystems services, pandemics and epidemic risk

Specific Conditions

Expected EU contribution per project: between EUR 4 and 6 Million

Indicative budget: Total budget for the topic is EUR 12 Million

Type of Action: Research and Innovation Action

Eligibility conditions: see Annex B

Technology Readiness Level: Activities are expected to archive TLR 3-5

Expected Outcome

Successful proposal will contribute to European Green Deal priorities and the EU biodiversity strategy for 2030, whilst supporting the EU's response to the coronavirus and other zoonotic outbreaks, in the context of EU's goal of leading just digital, economic and ecological transitions that will leave no one behind, One Health approaches, and the future European Health Union. **Projects results** are expected to contribute to [...]

Scope

Wildlife microbiomes, whether symbiotic, commensal or pathogenic, and their potential to spread by crossing interspecies barriers, eventually reaching humans via transitional interfaces (e.g. peri-urban, farming areas), are still largely unknown. [...] The impacts of land use and climate change on biodiversity, ecosystem services and pandemics should be also taken into account, as well as any recent IPBES reports on the links between biodiversity and pandemics [...]

Deconstructing a call text

HORIZON-CL6-2021-CLIMATE-01-06 Resilient livestock farming systems under climate change Specific conditions

Expected EU contribution per project

The EU estimates that an EU contribution of around EUR 12.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.

Indicative budget

The total indicative budget for the topic is EUR 12.00 million.

Type of Action

Research and Innovation Actions (RIA)

Deconstructing a call + example

- **Specific Conditions:** main information about the call
- **Expected Outcomes:** what is supposed to be achieved



Outcomes ... → Impact

- **Scope:** presents what exactly is expected to be done



Research Work to be done



Consortium

Work Consortium Impact Budget

HORIZON-HLTH-2022-DISEASE-06-03-two-stage: Vaccines 2.0 - developing the next generation of vaccines

Specific conditions	
<i>Expected EU contribution per project</i>	The Commission estimates that an EU contribution of around EUR 8.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.
<i>Indicative budget</i>	The total indicative budget for the topic is EUR 40.00 million.
<i>Type of Action</i>	Research and Innovation Actions

Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “*Tackling diseases and reducing disease burden*”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

- The scientific and clinical communities use the increased knowledge on pathogens and better understanding of the immune system’s role in infectious diseases to develop vaccines with improved efficacy.
- Vaccine manufacturers use more innovative and sustainable manufacturing technologies and improved GMP manufacturing know-how for producing the next generation of vaccines.
- A diversified portfolio of vaccine candidates ready for testing in clinical trials help policy makers and funders to make informed decisions about support to vaccine development.
- New innovative and improved design of preclinical/clinical studies that match the features of the next generation of vaccines is available for clinical community and regulators, and will shorten vaccine development time.

Scope: Infectious diseases, including antimicrobial resistant (AMR) infections, remain a major threat to health and health security in the EU and globally. The availability of more effective, accessible and affordable vaccines would provide the most cost-effective preventive measure against the health threat of epidemics and AMR pathogens. Vaccines against diseases, such as AIDS, tuberculosis (TB), malaria, neglected tropical diseases, hepatitis C and water-borne diseases are essential to achieve the WHO targets to control the spread of infectious diseases. The first generation of vaccines against some of the pathogens have proven to be suboptimal and not effective enough to protect the population. Many viruses of pandemic potential are variable in their surface antigen composition, and novel technologies are required to develop efficient vaccines against each new variant efficiently and in a short timeframe. To ensure that

more effective, accessible and affordable vaccines against all major infectious diseases become a reality, it is essential to sustain a diverse and modernised vaccine development pipeline.

Proposals should aim to diversify and accelerate the global vaccine research and development pipeline, and to strengthen the current leading role of the EU in vaccine research and development. Proposals should cover those pathogens, which still lack vaccines of sufficient efficacy, but where earlier efforts have already produced promising vaccine candidates.

The proposals should address several of the following areas:

- Innovation and integration of expertise and capabilities, including alignment of preclinical and clinical models, biomarker studies and new vaccine approaches from discovery to late stage development, from bench-based research to clinical development of promising preventive candidates.
- Application of iterative processes (including cross-learning, back-translation steps, integrative analysis of data) to allow exploitation and integration of novel findings between clinical, preclinical and discovery research and development.
- Deciphering mechanisms of protection of candidates, new approaches to antigen discovery and immunogen engineering, reverse vaccinology, evaluation of vaccines in novel platforms and technologies, novel adjuvants, innovative vaccine manufacturing approaches, relevant animal models, evaluation of alternative vaccine delivery routes.

Effective, evidence-based decision-making for progression of vaccine candidates in the pipeline based on transparent and objective portfolio management. Regulatory requirements be considered. Sex, gender, age and socio-economic factors should be taken into account.

Work	Consortium	Impact	Budget
------	------------	--------	--------

HORIZON-HLTH-2022-DISEASE-06-03-two-stage: Vaccines 2.0 - developing the next generation of vaccines

Specific conditions	
<i>Expected EU contribution per project</i>	The Commission estimates that an EU contribution of around EUR 8.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.
<i>Indicative budget</i>	The total indicative budget for the topic is EUR 40.00 million
<i>Type of Action</i>	Research and Innovation Actions

Work	Consortium	Impact	Budget
------	------------	--------	--------

Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 "Tackling diseases and reducing disease burden". To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

- The scientific and clinical communities use the increased knowledge on pathogens and better understanding of the immune system's role in infectious diseases to develop vaccines with improved efficacy.
- Vaccine manufacturers use more innovative and sustainable manufacturing technologies and improved GMP manufacturing know-how for producing the next generation of vaccines.
- A diversified portfolio of vaccine candidates ready for testing in clinical trials help policy makers and funders to make informed decisions about support to vaccine development.
- New innovative and improved design of preclinical/clinical studies that match the features of the next generation of vaccines is available for clinical community and regulators, and will shorten vaccine development time.

Scope: Infectious diseases, including antimicrobial resistant (AMR) infections, remain a major threat to health and health security in the EU and globally. The availability of more effective, accessible and affordable vaccines would provide the most cost-effective preventive measure against the health threat of epidemics and AMR pathogens. Vaccines against diseases, such as AIDS, tuberculosis (TB), malaria, neglected tropical diseases, hepatitis C and water-borne diseases are essential to achieve the WHO targets to control the spread of infectious diseases. The first generation of vaccines against some of the pathogens have proven to be suboptimal and not effective enough to protect the population. Many viruses of pandemic potential are variable in their surface antigen composition, and novel technologies are required to develop

efficient vaccines against each new variant efficiently and in a short timeframe. To ensure that more effective, accessible and affordable vaccines against all major infectious diseases become a reality, it is essential to sustain a diverse and modernised vaccine development pipeline.

Proposals should aim to diversify and accelerate the global vaccine research and development pipeline, and to strengthen the current leading role of the EU in vaccine research and development. Proposals should cover those pathogens, which still lack vaccines of sufficient efficacy, but where earlier efforts have already produced promising vaccine candidates.

The proposals should address several of the following areas:

- Innovation and integration of expertise and capabilities, including alignment of preclinical and clinical models, biomarker studies and new vaccine approaches from discovery to late stage development, from bench-based research to clinical development of promising preventive candidates.
 - Application of iterative processes (including cross-learning, back-translation steps, integrative analysis of data) to allow exploitation and integration of novel findings between clinical, preclinical and discovery research and development.
 - Deciphering mechanisms of protection of candidates, new approaches to antigen discovery and immunogen engineering, reverse vaccinology, evaluation of vaccines in novel platforms and technologies, novel adjuvants, innovative vaccine manufacturing approaches, relevant animal models, evaluation of alternative vaccine delivery routes.
- Effective, evidence-based decision-making for progression of vaccine candidates in the pipeline based on transparent and objective portfolio management. Regulatory requirements be considered. Sex, gender, age and socio-economic factors should be taken into account.

Group Work: Selecting and advertising HEU Calls

- Research of relevant calls by using the respective work programmes and/or Search Tools (Funding & Tenders Portal)
 - Focus on your clients/target group
- Decode and select the “right” calls
- Develop mechanisms and strategies to present them to relevant stakeholders
 - the research and innovation community
 - particular promising actors
- Refine and present selected calls to stakeholders in a targeted approach. Consider use of formats and media for each case!

Group Work: Selecting and advertising HEU Calls

Divide into groups:

1. ICT (IT services, interoperability, AI, cybersecurity)
2. Art & Humanities / Cultural Heritage
3. Food and Agriculture (Food quality and safety, future farming, and new technologies)
4. Renewable Energy (research capacity and infrastructure, green hydrogen, solar energy)
5. Innovative Health System (research support, bacteriophages and herbal medicine)
6. Circular Economy/Waste Management

Summarise and describe your results and present to the whole group (select 1 person to do so)

Horizon Europe structure



Pillar I

EXCELLENT SCIENCE

- European Research Council
- Marie Skłodowska-Curie
- Research Infrastructures



Pillar II

GLOBAL CHALLENGES & EUROPEAN INDUSTRIAL COMPETITIVENESS

6 Clusters

- Health
- Culture, Creativity & Inclusive Society
- Civil Security for Society
- Digital, Industry & Space
- Climate, Energy & Mobility
- Food, Bioeconomy, Natural Resources, Agriculture & Environment
- Joint Research Centre




Pillar III

INNOVATIVE EUROPE

- European Innovation Council
- European Innovation Ecosystems
- European Institute of Innovation & Technology

WIDENING PARTICIPATION AND STRENGTHENING THE EUROPEAN RESEARCH AREA

- Widening participation & spreading excellence
- Reforming & Enhancing the European R&I system



Thank you!

HorizonEU

<http://ec.europa.eu/horizon-europe>



© European Union 2021

Unless otherwise noted the reuse of this presentation is authorised under the [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.

Image credits: © ivector #235536634, #249868181, #251163013, #266009682, #273480523, #362422833, #241215668, #244690530, #245719946, #251163053, #252508849, 2020. Source: Stock.Adobe.com. Icons © Flaticon – all rights reserved.